0.1380SEK+2.22%Mkt Cap: 91.30M SEKP/E: —Last update: 2026-05-13
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI con…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-1.97
PEG—
P/B3.00
P/S18.93
EV/EBITDA-1.87
EV/Revenue10.38
EPS (TTM)-0.06
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-19.19%
FCF Margin-363.29%
Operating CF-28.30M SEK
CapEx (TTM)—
Net Debt/EBITDA1.11
Net Debt-29.67M SEK
Technical
SMA 500.1163 (+18.6%)
SMA 2000.1547 (-10.8%)
Beta1.30
S&P 52W Chg24.23%
Avg Vol (30d)457.42K
Avg Vol (10d)1.01M
Technical Indicators
RSI (14)62.5
MACD0.0042
MACD Signal0.0022
MACD Hist.+0.0020
BB Upper0.1355 SEK
BB Middle0.1203 SEK
BB Lower0.1052 SEK
BB Width25.19%
ATR (14)0.0130 SEK
Vol Ratio (20d)0.17x
52W Range
0.084214% of range0.4600
52W High0.4600 SEK
52W Low0.0842 SEK
Profitability
Gross Margin-2527.23%
EBITDA Margin0.00%
Profit Margin-6076.43%
Oper. Margin-733.49%
ROE-86.37%
ROA-72.39%
Revenue Growth-55.10%
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio6.96
Quick Ratio5.77
Book Value/Sh0.0460 SEK
Cash/Share0.0450 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.661.57M
Float424.27M
Insiders38.74%
Institutions1.80%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)0.2900 SEK
Target Range0.2900 SEK – 0.2900 SEK
# Analysts1
Company
Market Cap91.30M SEK
Enterprise Value50.05M SEK
Revenue (TTM)4.82M SEK
Gross Profit-11.04M SEK
Net Income (TTM)-26.55M SEK
Revenue/Share0.0130 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees5
Last Price0.1380 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—